(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 October 2021 (14.10.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/207335 A1

(51) International Patent Classification:
C07D 487/10 (2006.01) *A61P 35/02* (2006.01)
C07D 471/10 (2006.01)

(21) International Application Number:
PCT/US2021/026141

(22) International Filing Date:
07 April 2021 (07.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/006,574 07 April 2020 (07.04.2020) US

(71) Applicant: **SYNDAX PHARMACEUTICALS, INC.** [US/US]; 35 Gatehouse Drive, Building D, Floor 3, Waltham, Massachusetts 02451 (US).

(72) Inventors: **MCGEEHAN, Gerard M.**; 3741 Rosemont Pass, Newton Square, Pennsylvania 19073 (US). **ORDENTLICH, Peter**; 28 Slocum Road, Lexington, Massachusetts 02421 (US). **ROSEN, Galit**; 21 Moreland Avenue, Newton, Massachusetts 02459 (US). **SMITH, Steven A.**; 88 Bush Street, Unit 3145, San Jose, California 95126 (US).


(74) Agent: **OWENS, Eric A.** et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF

FIGURE 1



Subject	Dose	Posaconazole	$ssAUC_{0-24}$ (ng*h/mL)
05-001	113 mg BID	No	12600
04-001	226 mg BID	Yes	85700

(57) Abstract: The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-MLL interaction.

WO 2021/207335 A1

[Continued on next page]

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*